文献速递关节外科创伤骨科

不可持续的全髋翻修术报销模式:12年补偿分析

An Unsustainable Reimbursement Model: A 12-Year Analysis of Compensation for Revision Total Hip Arthroplasty.
PubMed 文献 · J Arthroplasty · 2026-04-27

该研究基于全国索赔数据库分析2010至2022年无菌性和感染性全髋翻修术的医生和90天诊疗 episode 报销趋势,发现报销整体停滞,无法反映手术复杂性增加, Medicare 计划报销始终低于商业保险,威胁患者获得该必要手术服务的可持续性。

要点

  • 全髋翻修术报销12年来停滞,未反映手术复杂性增加。
  • Medicare 计划报销持续低于商业保险,90天诊疗 episode 报销显著下降。
  • 无菌性和感染性再植入手术报销无增长,威胁护理可持续性。

核心结论

  • 全髋翻修术报销在过去12年停滞,未能反映手术复杂性增加; Medicare 计划报销始终低于商业保险,无菌性和感染性再植入手术报销无增长,威胁患者获得必要手术服务的可持续性,需紧急政策改革。

研究设计与样本

  • 使用全国索赔数据库,识别2010至2022年间接受无菌性或感染性全髋翻修术的患者,排除清创、抗生素和植入物保留手术,共纳入57,821例无菌手术和17,379例感染手术,按保险类型分组分析年度平均报销金额并调整通货膨胀。

主要发现

  • 商业保险的感染手术在12年间医生报销平均差异变化为$1,525.3(P < 0.001),90天诊疗 episode 报销平均差异变化为$529.9(P < 0.001)。
  • 与2010年相比,2022年 Medicare 和 Medicare-Advantage 组医生报销略有增加,但90天诊疗 episode 报销显著下降( Medicare 平均差异变化为$-2,889.3,P < 0.001; Medicare-Advantage 平均差异变化为$-1,601.3,P < 0.001)。
  • 单阶段和取出术报销持续略有增加,但无菌翻修和再植入手术报销在整个12年期间停滞。

临床怎么用

  • 临床医生应了解全髋翻修术报销停滞和 Medicare 计划报销低于商业保险的现状,关注报销政策变化对手术可持续性和患者可及性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Revision total hip arthroplasty (rTHA) is a complex and resource-intensive procedure. However, physician and hospital compensations have not evolved to reflect such complexity. Therefore, we sought to describe trends in (1) physician, (2) 90-day episode-of-care, and (3) procedure type reimbursements during a 12-year period. METHODS: Using a national claims database, we identified patients who underwent aseptic or septic rTHA between 2010 and 2022 using current-procedural terminology (CPT) and international-classification-of-diseases 9/10 codes. Debridement, antibiotics, and implant retention procedures were excluded. A total of 57,821 aseptic and 17,379 septic procedures were identified. The mean dollar reimbursement was calculated each year and adjusted for inflation. Patients were grouped by insurance type: (1) Commercial, (2) Medicare-Advantage (MCR-A), and (3) Medicare (MCR). A subgroup analysis compared septic revisions based on procedure types. RESULTS: Commercially insured septic procedures showed the highest increase in physician (mean difference change of $1,525.3, P < 0.001) and 90-day episode-of-care (mean difference change of $529.9, P < 0.001) reimbursements during the 12-year period. Although compared to 2010, physician reimbursement in 2022 had a slight increase in the MCR and MCR-A groups, 90-day episode-of-care reimbursement was significantly decreased (MCR mean difference change of $-2,889.3, P < 0.001; MCR-A mean difference change of $-1,601.3, P < 0.001). Regarding procedure types, single-stage and explantation had a constant slight increase in reimbursement, but aseptic revisions' and reimplantation procedures' reimbursement remained stagnant throughout the 12-year period. CONCLUSIONS: Reimbursement for rTHA has remained stagnant over the past 12 years and fails to reflect increasing procedural complexity. Medicare-based plans consistently underperform compared to commercial payers, and the lack of growth in payments for aseptic and septic reimplantations threatens the sustainability of care for these patients. Urgent policy reform is needed to align reimbursement with clinical resource demands, ensure equitable compensation, and preserve patient access to this essential surgical service.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Bernabe KD, Lizcano JD, Villa JM, et al. An Unsustainable Reimbursement Model: A 12-Year Analysis of Compensation for Revision Total Hip Arthroplasty. J Arthroplasty. 2026. PMID: 42055227. doi:10.1016/j.arth.2026.04.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。